A IOURNAL OF NEUROLOGY

LETTER TO THE EDITOR

Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis

Janel O. Johnson,¹ Shannon M. Glynn,¹ J. Raphael Gibbs,² Mike A. Nalls,³ Mario Sabatelli,⁴ Gabriella Restagno,⁵ Vivian E. Drory,⁶ Adriano Chiò,⁷ Ekaterina Rogaeva⁸ and Bryan J. Traynor¹

- 1 Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892, USA
- 2 Computational Biology Core, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892, USA
- 3 Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD 20892, USA

- 6 Department of Neurology, Sourasky Medical Centre, 6 Weizmann Street, Tel Aviv 64239, Israel
- 7 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin 10124, Italy
- 8 Tanz Centre for Research of Neurodegenerative Diseases, Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario M5S 3H2, Canada

Correspondence to: Bryan J. Traynor, MD PhD, Laboratory of Neurogenetics, NIA, NIH, 35 Convent Drive, Bethesda, MD 20892, USA E-mail: traynorb@mail.nih.gov

Sir,

A recent study by Bannwarth and colleagues has shown that variation in the CHCHD10 gene is a cause of familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (Bannwarth et al., 2014). The study identified a c.176C > T (p.Ser59Leu, NM_213720.1) missense mutation in a multigenerational kindred. In the present study, we performed genome sequencing of four affected individuals from a large ALS family (USALS#5). This identified a G to T transversion at position c.44 (chr22:24,109,778, hg19) that segregated with disease within this pedigree and leads to a p.R15L amino acid change in exon two of the CHCHD10 mitochondrial protein. Previous attempts to identify the causative mutation in this family using an exome sequencing approach failed to identify this variant due to poor sequence coverage in this genomic region. The variant was not described as a human polymorphism in the Single Nucleotide Polymorphism (SNP) database (http://www.ncbi.nlm.nih.gov/ SNP/, build 141) and was not found in 1158 control individuals of the Exome Sequencing Project (http://snp.gs.washington.edu/ SeattleSeqAnnotation138/).

To further assess the mutation burden in patients, we Sanger sequenced all exons of *CHCHD10* in an additional series of 84 patients diagnosed with familial ALS according to the El Escorial

criteria (Brooks, 1994). These samples did not carry the *C9orf72* hexanucleotide repeat expansion or known mutations in ALS genes including *SOD1*, *TARDBP*, *FUS*, *VCP*, *PFN1*, *UBQLN1*, *MATR3*, *SQSTM1*, *OPTN*, and *HNPNPA2B1* (Renton *et al.*, 2014). The ethical review boards at each institution approved the study, and all participants provided informed consent.

Our mutational screening of *CHCHD10* identified the same p.R15L mutation discovered in the USALS#5 family in two additional familial ALS cases (www.coriell.org, ND10928 and ND11809). Analysis of genome-wide SNP chip data indicates that all six patients carrying the p.R15L variant share a 6.2 Mb haplotype across the gene.

Our data demonstrate that mutations in *CHCHD10* are a relatively common cause of familial ALS and that pathogenic variants are concentrated in exon 2. This represents the first time, to our knowledge, that genome sequencing has been applied to familial ALS. The primary advantage of this methodology is improved coverage of protein-coding regions of the genome, particularly in GC-rich regions that may not be effectively captured by the oligonucleotide baits that are central to exome sequencing. It is also noteworthy that patients in the pedigree reported by Bannwarth and colleagues had reliable evidence of mitochondrial myopathy. Two other ALS genes, *VCP* and *MATR3*, have been

⁴ Neurological Institute, Catholic University and Insieme Contro le Malattie del Motoneurone Association for ALS Research, Largo Agostino Gemelli 8, Rome 00168, Italy

⁵ Molecular Genetics Unit, Department of Clinical Pathology, Azienda Sanitaria Ospedaliera Ospedale Infantile Regina Margherita-Santa Anna, Turin 10126, Italy

Advance Access publication September 27, 2014

Published by Oxford University Press on behalf of the Guarantors of Brain 2014. This work is written by US Government employees and is in the public domain in the US.

associated with clinical myopathy (Johnson *et al.*, 2010, 2014), suggesting that muscle involvement may be more common in familial ALS than previously appreciated.

Acknowledgements

DNA samples for this study were obtained in part from the National Institute of Neurological Disorders and Stroke (NINDS) repository at the Coriell Cell Repositories (http://www.coriell. org/). We thank the patients and research subjects who contributed samples for this study.

Funding

This work was supported in part by the Intramural Research Programs of the US National Institutes of Health (NIH), National Institute on Ageing (Z01-AG000949-02) and NINDS. The work was also supported by the Packard Centre for ALS Research at Johns Hopkins, ALS Association, Muscular Dystrophy Association, Ontario Research Fund, Italian Health Ministry, Fondazione Vialli e Mauro Onlus, Federazione Italiana Giuoco Calcio, Compagnia di San Paolo, Adelis Foundation, European Community's Health Seventh Framework Programme (FP7/2007-2013) under grant agreements 259867.

References

- Bannwarth S, Ait-El-Mkadem S, Chaussenot A, Genin EC, Lacas-Gervais S, Fragaki K, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 2014; 137 (Pt 8): 2329–45.
- Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis' workshop contributors. J Neurol Sci 1994; 124: 96–107.
- Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68: 857–64.
- Johnson JO, Pioro EP, Boehringer A, Chia R, Feit H, Renton AE, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci 2014; 17: 664–6.
- Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014; 17: 17–23.